Kunming Longjin Pharmaceutical Co Ltd (002750) — Net Asset Quality Index
Kunming Longjin Pharmaceutical Co Ltd (002750) has a Net Asset Quality Index of 87.4% as of March 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥555.15 Million minus total liabilities of CN¥69.96 Million yields net assets of CN¥485.19 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Kunming Longjin Pharmaceutical Co Ltd (002750) asset resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Kunming Longjin Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Kunming Longjin Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of March 2025, the index stands at 87.4%, representing net assets of CN¥485.19 Million against total assets of CN¥555.15 Million CNY. See Kunming Longjin Pharmaceutical Co Ltd (002750) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 002750 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 86.0% | CN¥494.21 Million | CN¥574.40 Million | CN¥80.19 Million | ▲ +0.4 pp |
| 2023 | 85.7% | CN¥541.13 Million | CN¥631.63 Million | CN¥90.51 Million | ▲ +4.7 pp |
| 2022 | 80.9% | CN¥604.77 Million | CN¥747.21 Million | CN¥142.44 Million | ▼ -1.1 pp |
| 2021 | 82.0% | CN¥678.29 Million | CN¥827.28 Million | CN¥148.99 Million | ▼ -1.7 pp |
| 2020 | 83.7% | CN¥704.71 Million | CN¥841.76 Million | CN¥137.05 Million | ▲ +1.2 pp |
| 2019 | 82.5% | CN¥665.89 Million | CN¥806.89 Million | CN¥141.00 Million | ▼ -0.8 pp |
| 2018 | 83.3% | CN¥655.93 Million | CN¥787.55 Million | CN¥131.62 Million | ▲ +1.1 pp |
| 2017 | 82.2% | CN¥645.54 Million | CN¥785.23 Million | CN¥139.69 Million | ▼ -6.0 pp |
| 2016 | 88.3% | CN¥670.46 Million | CN¥759.68 Million | CN¥89.22 Million | ▲ +2.5 pp |
| 2015 | 85.8% | CN¥599.41 Million | CN¥698.86 Million | CN¥99.45 Million | ▲ +20.2 pp |
| 2014 | 65.6% | CN¥285.57 Million | CN¥435.59 Million | CN¥150.02 Million | ▼ -2.7 pp |
| 2013 | 68.2% | CN¥302.00 Million | CN¥442.56 Million | CN¥140.57 Million | ▲ +6.6 pp |
| 2012 | 61.7% | CN¥226.94 Million | CN¥368.05 Million | CN¥141.11 Million | ▼ -3.3 pp |
| 2011 | 65.0% | CN¥186.74 Million | CN¥287.36 Million | CN¥100.62 Million | — |